Moderna Delivers Surprise Profit, Raises 2026 Outlook

What happened

Moderna reported third-quarter revenue of $1.31 billion, up 29% from a year earlier, and net income of $162 million, reversing a $200 million loss. It raised its full-year revenue growth outlook to a range from 15% to 25%, from no more than 10%, and lowered planned 2026 research and development spending to about $2.7 billion.

Confirmed

Global impact / market context

The stronger revenue outlook suggests COVID-19 vaccine sales may support Moderna’s recovery for longer than previously expected. Lower planned research spending could also reduce cash outflows, leaving more funds for its expansion into cancer treatments and other vaccines, though execution and future demand remain uncertain.

Analyst inference

Moderna remains heavily dependent on COVID-19 vaccines, while it is also developing influenza, respiratory syncytial virus and personalized cancer treatments. That concentration means changes in vaccine demand can quickly affect revenue and cash available to fund research and the move into new products.

Analyst inference

What to watch

1. Compare later revenue reports with management’s raised full-year growth outlook; results below the projected range could weaken confidence that vaccine demand is sustaining the financial recovery. Analyst inference
2. Track whether the company keeps 2026 research and development spending near its revised outlook, since higher costs could reduce cash available for vaccine and cancer-treatment development. Analyst inference
3. Watch future updates on international COVID-19 vaccine demand, which drove much of the reported improvement, and whether sales from other vaccines or cancer treatments expand. Analyst inference

Evidence

• gurufocus.com